For decades, the standard medical approach to treating osteoporosis has been defensive. Most first-line treatments rely on antiresorptive agents, which work by slowing down the rate at which the body breaks down bone. While effective at preventing further loss, these drugs do not actively “build” new skeletal mass.
A newer class of medication, known as anabolic agents, is shifting this paradigm from defense to offense. Instead of merely slowing bone loss, these drugs actively stimulate the body to create new bone, offering a more proactive way to strengthen the skeleton and reduce fracture risks.
How Anabolic Agents Work: Rebuilding the Skeleton
Unlike traditional treatments, anabolic agents target osteoblasts —the cells responsible for bone formation. By stimulating these cells, the medication mimics the natural bone-building processes that occur during childhood and adolescence.
Medical experts describe the effect as a structural repair process. Dr. Susan Bukata of the University of California, San Diego, compares the action of these drugs to “filling in a pothole” or reconnecting broken segments of a walkway. This dual action—creating new bone and repairing existing structural gaps—makes the skeleton more resilient.
The Three FDA-Approved Anabolic Therapies
Currently, there are three primary anabolic treatments approved by the U.S. Food and Drug Administration (FDA), each utilizing different biological mechanisms:
- Abaloparatide (Tymlos): A daily subcutaneous injection that mimics the parathyroid hormone to trigger the growth of new bone cells.
- Teriparatide (Forteo): Also a daily subcutaneous injection, this medication mimics the parathyroid hormone to stimulate bone and cartilage growth.
- Romosozumab (Evenity): A monthly injection administered by a healthcare provider. As a monoclonal antibody, it works by inhibiting sclerostin (a protein that limits bone growth), effectively increasing bone mass while also acting as an antiresorptive to slow bone loss.
Who Should Consider Anabolic Treatment?
Because these medications are more potent and specialized than standard treatments, they are not typically prescribed as a first-line option for everyone. Instead, doctors reserve them for patients at high or very high risk of fracture.
Clinical indicators for this treatment include:
– History of fractures: Patients who have already experienced at least one bone break.
– Low bone density: Specifically those with a T-score of -2.8 or lower on a bone mineral density test.
– Treatment resistance: Patients who continue to lose bone mass despite taking other medications (such as long-term steroid users).
Clinical Trend: Current research suggests that for high-risk patients, the most effective long-term strategy may be a “sequential” approach: using anabolic agents to build bone strength first, followed by antiresorptive medications to maintain those gains.
Safety, Side Effects, and Contraindications
While highly effective, anabolic agents require careful medical supervision due to their potency and potential side effects.
Common Side Effects
Patients may experience various symptoms, including:
– Nausea and dizziness
– Headache
– Joint, bone, or muscle pain
– Injection site reactions
– Hypercalcemia/Hypercalciuria: Elevated calcium levels in the blood or urine.
Critical Precautions
Certain medical histories may make these drugs unsafe:
– Cardiovascular Risks: Romosozumab may increase the risk of heart problems; it is generally contraindicated for those who have suffered a heart attack or stroke within the last year.
– Bone Disease: These drugs are typically not recommended for those with bone cancer or a history of radiation to the skeleton.
– Dental Health: There is a noted risk of severe jaw issues during dental procedures for patients on certain bone therapies.
Summary
Anabolic agents represent a significant advancement in bone health by actively stimulating new bone formation rather than just slowing its loss. While they offer a powerful solution for high-risk patients, their use must be carefully balanced against individual cardiovascular and bone health histories.
